Financials

v3.21.1
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 5,413 $ 5,223
Receivables 884 438
Inventory 328 563
Prepaid expenses and other current assets 522 534
Discontinued operations - current assets 181 1,550
Total current assets 7,328 8,308
Property and equipment, net 618 817
Operating lease right-of-use asset 141 397
Total Assets 8,087 9,522
Current liabilities:    
Accounts payable 1,253 815
Accrued clinical trials expenses 214 169
Other accrued liabilities 319 264
Operating lease liability, current 150 272
Current portion of long-term debt 327 0
Discontinued operations - current liabilities 1,960 2,080
Total current liabilities 4,223 3,600
Long-term debt, net of debt discount of $0 and $346 332 4,019
Warrant liability 0 320
Operating lease liability, non-current 0 150
Total liabilities 4,555 8,089
Commitments and contingencies (Note 5)
Stockholders' equity    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2020 and 2019. 0 0
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 7,139,068 and 1,912,627 shares issued and outstanding at December 31, 2020 and 2019, respectively. 7 2
Additional paid-in capital 370,804 350,468
Accumulated deficit (367,279) (349,037)
Total stockholders' equity 3,532 1,433
Total liabilities and stockholders' equity $ 8,087 $ 9,522

Source

v3.21.1
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenue:    
Total revenue $ 4,838 $ 2,605
Operating expenses:    
Cost of goods sold 472 0
Research and development 5,916 5,080
General and administrative 5,801 5,401
Total operating expenses 12,189 10,481
Loss from operations (7,351) (7,876)
Other income (expense):    
Interest expense, net (769) (967)
Other income (expense), net (258) 17
Non-cash gain (loss) on changes in the fair value of warrants (923) 1,110
Non-cash gain on changes in the fair value of assets 1,975 0
Non-cash gain (loss) on debt extinguishment (81) 226
Other income (expense), net (56) 386
Loss from continuing operations (7,407) (7,490)
Loss on discontinued operations (10,835) (8,968)
Net loss and comprehensive loss $ (18,242) $ (16,458)
Basic and diluted net loss per common share from continuing operations $ (1.96) $ (9.78)
Basic and diluted net loss per common share on discontinued operations $ (2.87) $ (11.71)
Weighted average shares used in computing basic and diluted net loss per common share 3,773 766
License revenue    
Revenue:    
Total revenue $ 11 $ 315
Product revenue    
Revenue:    
Total revenue 528 0
Grant revenue    
Revenue:    
Total revenue $ 4,299 $ 2,290

Source

v3.21.1
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:    
Net loss $ (18,242) $ (16,458)
Adjustments to reconcile net loss to net cash used in operating activities:    
Non-cash gain on difference between fair and carrying value of assets transferred in debt settlement (1,975) 0
Depreciation and amortization 292 244
Non-cash interest expense 498 613
Non-cash loss (gain) on changes in fair value of warrants 923 (1,110)
Non-cash loss (gain) on debt extinguishment 81 (226)
Stock-based compensation 7 572
Finance costs for issuance of warrants 211 0
Other (16) (41)
Changes in operating assets and liabilities:    
Receivables 186 744
Inventory 287 264
Contract assets 0 99
Prepaid expenses and other assets 391 (547)
Accounts payable 1,101 (125)
Accrued sales allowances (747) 809
Other accrued liabilities (200) 30
Deferred revenue 0 (313)
Net cash used in operating activities (17,203) (15,445)
Cash flows from investing activities:    
Purchases of furniture and equipment (540) (256)
Net cash used in investing activities (540) (256)
Cash flows from financing activities:    
Proceeds from equity offerings 11,636 9,665
Net loan proceeds 654 0
Proceeds from the exercise of warrants 7,243 1,603
Payments of long-term debt (1,600) 0
Net cash provided by financing activities 17,933 11,268
Net increase (decrease) in cash 190 (4,433)
Cash, cash equivalents and restricted cash at beginning of period 5,223 9,656
Cash, cash equivalents and restricted cash at end of period 5,413 5,223
Supplemental disclosure of cash flow information:    
Interest paid 295 432
Purchases of property and equipment in accounts payable or accrued expenses $ 0 $ 11

Source